Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | REPL |
---|---|---|
09:32 ET | 104544 | 8.17 |
09:34 ET | 2937 | 7.88 |
09:36 ET | 5600 | 7.87 |
09:38 ET | 1737 | 7.995 |
09:39 ET | 3298 | 8.03 |
09:41 ET | 1550 | 8.11 |
09:43 ET | 16562 | 8.24 |
09:45 ET | 15262 | 8.16 |
09:48 ET | 3019 | 8.25 |
09:50 ET | 3741 | 8.24 |
09:52 ET | 26434 | 8.315 |
09:54 ET | 7507 | 8.235 |
09:56 ET | 5083 | 8.2011 |
09:57 ET | 22271 | 8.115 |
09:59 ET | 7425 | 8.185 |
10:01 ET | 4769 | 8.205 |
10:03 ET | 1348 | 8.19 |
10:06 ET | 3608 | 8.2 |
10:08 ET | 3325 | 8.185 |
10:10 ET | 1851 | 8.16 |
10:12 ET | 2500 | 8.155 |
10:14 ET | 2849 | 8.08 |
10:15 ET | 2900 | 8.125 |
10:17 ET | 4082 | 8.14 |
10:19 ET | 900 | 8.18 |
10:21 ET | 3922 | 8.18 |
10:24 ET | 800 | 8.185 |
10:26 ET | 1087 | 8.2 |
10:28 ET | 1400 | 8.21 |
10:30 ET | 4025 | 8.205 |
10:32 ET | 4622 | 8.16 |
10:33 ET | 500 | 8.19 |
10:35 ET | 2584 | 8.18 |
10:37 ET | 600 | 8.2 |
10:39 ET | 1395 | 8.195 |
10:42 ET | 4449 | 8.19 |
10:44 ET | 4907 | 8.2 |
10:46 ET | 6294 | 8.35 |
10:48 ET | 7252 | 8.4 |
10:50 ET | 4442 | 8.45 |
10:51 ET | 9523 | 8.5 |
10:53 ET | 4197 | 8.52 |
10:55 ET | 4202 | 8.5 |
10:57 ET | 8716 | 8.5 |
11:00 ET | 3684 | 8.44 |
11:02 ET | 1735 | 8.47 |
11:04 ET | 1512 | 8.47 |
11:06 ET | 5583 | 8.45 |
11:08 ET | 5526 | 8.48 |
11:09 ET | 4378 | 8.46 |
11:11 ET | 2895 | 8.44 |
11:13 ET | 3450 | 8.44 |
11:15 ET | 6749 | 8.455 |
11:18 ET | 2337 | 8.5 |
11:20 ET | 1800 | 8.51 |
11:22 ET | 1300 | 8.51 |
11:24 ET | 4510 | 8.57 |
11:26 ET | 17738 | 8.598 |
11:27 ET | 2095 | 8.58 |
11:29 ET | 3905 | 8.57 |
11:31 ET | 4691 | 8.59 |
11:33 ET | 3478 | 8.6 |
11:36 ET | 5054 | 8.595 |
11:38 ET | 3949 | 8.59 |
11:40 ET | 200 | 8.6 |
11:42 ET | 2998 | 8.57 |
11:44 ET | 3227 | 8.54 |
11:45 ET | 2880 | 8.52 |
11:47 ET | 7796 | 8.555 |
11:49 ET | 1000 | 8.53 |
11:51 ET | 1472 | 8.545 |
11:54 ET | 1242 | 8.56 |
11:56 ET | 500 | 8.585 |
11:58 ET | 4773 | 8.58 |
12:00 ET | 4147 | 8.56 |
12:02 ET | 87798 | 8.54 |
12:03 ET | 1493 | 8.54 |
12:05 ET | 5520 | 8.58 |
12:07 ET | 4441 | 8.58 |
12:09 ET | 5380 | 8.59 |
12:12 ET | 3585 | 8.6 |
12:14 ET | 7534 | 8.55 |
12:16 ET | 1749 | 8.5 |
12:18 ET | 2500 | 8.53 |
12:20 ET | 1392 | 8.51 |
12:21 ET | 3370 | 8.51 |
12:23 ET | 4659 | 8.51 |
12:25 ET | 3879 | 8.57 |
12:27 ET | 3216 | 8.54 |
12:30 ET | 1452 | 8.56 |
12:32 ET | 2765 | 8.6 |
12:34 ET | 3138 | 8.59 |
12:36 ET | 17311 | 8.59 |
12:38 ET | 2700 | 8.6 |
12:39 ET | 12025 | 8.6 |
12:41 ET | 5971 | 8.6 |
12:43 ET | 7024 | 8.67 |
12:45 ET | 4655 | 8.6 |
12:48 ET | 1424 | 8.63 |
12:50 ET | 2251 | 8.62 |
12:52 ET | 2648 | 8.64 |
12:54 ET | 1442 | 8.67 |
12:56 ET | 5481 | 8.6805 |
12:57 ET | 2237 | 8.71 |
12:59 ET | 4502 | 8.73 |
01:01 ET | 1935 | 8.71 |
01:03 ET | 2462 | 8.685 |
01:06 ET | 2160 | 8.69 |
01:08 ET | 2192 | 8.66 |
01:10 ET | 1543 | 8.656 |
01:12 ET | 3309 | 8.63 |
01:14 ET | 4948 | 8.67 |
01:15 ET | 1941 | 8.6799 |
01:17 ET | 1700 | 8.69 |
01:19 ET | 2303 | 8.72 |
01:21 ET | 3864 | 8.8 |
01:24 ET | 2318 | 8.8116 |
01:26 ET | 8152 | 8.795 |
01:28 ET | 6222 | 8.83 |
01:30 ET | 3725 | 8.8 |
01:32 ET | 1900 | 8.82 |
01:33 ET | 900 | 8.85 |
01:35 ET | 1700 | 8.85 |
01:37 ET | 1540 | 8.83 |
01:39 ET | 2236 | 8.84 |
01:42 ET | 3173 | 8.84 |
01:44 ET | 16662 | 8.75 |
01:46 ET | 6366 | 8.73 |
01:48 ET | 4455 | 8.78 |
01:50 ET | 7191 | 8.75 |
01:51 ET | 1902 | 8.76 |
01:53 ET | 1535 | 8.77 |
01:55 ET | 4946 | 8.7 |
01:57 ET | 30319 | 8.77 |
02:00 ET | 7507 | 8.73 |
02:02 ET | 1709 | 8.76 |
02:04 ET | 3000 | 8.77 |
02:06 ET | 1300 | 8.79 |
02:08 ET | 5626 | 8.75 |
02:09 ET | 3668 | 8.74 |
02:11 ET | 2167 | 8.72 |
02:13 ET | 6424 | 8.75 |
02:15 ET | 2300 | 8.78 |
02:18 ET | 3510 | 8.78 |
02:20 ET | 15463 | 8.7 |
02:22 ET | 2463 | 8.69 |
02:24 ET | 2021 | 8.68 |
02:26 ET | 3636 | 8.71 |
02:27 ET | 1725 | 8.73 |
02:29 ET | 4638 | 8.72 |
02:31 ET | 6604 | 8.7 |
02:33 ET | 3358 | 8.665 |
02:36 ET | 1529 | 8.66 |
02:38 ET | 11672 | 8.59 |
02:40 ET | 8491 | 8.57 |
02:42 ET | 4961 | 8.57 |
02:44 ET | 5503 | 8.54 |
02:45 ET | 4464 | 8.56 |
02:47 ET | 5434 | 8.55 |
02:49 ET | 6398 | 8.57 |
02:51 ET | 6406 | 8.49 |
02:54 ET | 6352 | 8.48 |
02:56 ET | 2200 | 8.51 |
02:58 ET | 6226 | 8.5 |
03:00 ET | 6576 | 8.49 |
03:02 ET | 2000 | 8.5 |
03:03 ET | 6455 | 8.51 |
03:05 ET | 6241 | 8.51 |
03:07 ET | 6792 | 8.5 |
03:09 ET | 10482 | 8.54 |
03:12 ET | 6300 | 8.53 |
03:14 ET | 6134 | 8.55 |
03:16 ET | 6091 | 8.55 |
03:18 ET | 6125 | 8.55 |
03:20 ET | 6008 | 8.53 |
03:21 ET | 3815 | 8.52 |
03:23 ET | 5937 | 8.5 |
03:25 ET | 9434 | 8.55 |
03:27 ET | 28289 | 8.51 |
03:30 ET | 6350 | 8.51 |
03:32 ET | 25583 | 8.4 |
03:34 ET | 29367 | 8.39 |
03:36 ET | 13127 | 8.36 |
03:38 ET | 26989 | 8.34 |
03:39 ET | 21303 | 8.345 |
03:41 ET | 34447 | 8.295 |
03:43 ET | 29984 | 8.275 |
03:45 ET | 26342 | 8.235 |
03:48 ET | 34055 | 8.28 |
03:50 ET | 38568 | 8.385 |
03:52 ET | 139881 | 8.28 |
03:54 ET | 71907 | 8.265 |
03:56 ET | 193049 | 8.52 |
03:57 ET | 69902 | 8.435 |
03:59 ET | 7043027 | 8.5 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Replimune Group Inc | 570.2M | -2.6x | --- |
Celcuity Inc | 559.2M | -5.7x | --- |
PepGen Inc | 553.0M | -5.3x | --- |
Northwest Biotherapeutics Inc | 555.8M | -7.3x | --- |
Mineralys Therapeutics Inc | 597.8M | -5.5x | --- |
Arrivent Biopharma Inc | 602.9M | 0.0x | --- |
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $570.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.24 |
EPS | $-3.24 |
Book Value | $6.10 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.